DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/b3fhfr/bcell) has announced the addition of the "B-Cell Leukemia-Pipeline Insights" report to their offering.
B-Cell Leukemia Pipeline Insights provides the in-depth analysis of the pipeline assets across the B-Cell Leukemia. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The B-Cell Leukemia Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.
B-Cell Leukemia Pipeline Insights Report covers the B-Cell Leukemia pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. The Report also provides B-Cell Leukemia related therapeutic assessments by molecule type, route of administration, monotherapy and combination products. The Report also highlights the discontinued and inactive projects in pipeline for B-Cell Leukemia.
Scope
- The report provides a B-Cell Leukemia Landscape across the globe
- The report provides drug profiles which includes product description, MOA, licensors & collaborators, technology, development partner and chemical information
- Coverage of the B-Cell Leukemia pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for B-Cell Leukemia and also provide company profiling
- Pipeline products coverage based on various stages of development from NDA filings to discovery.
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
For more information visit http://www.researchandmarkets.com/research/b3fhfr/bcell
